术后同步放化疗治疗ⅠB1~Ⅱ期高危宫颈癌患者的疗效及安全性  

Efficacy and safety of postoperative concurrent radiochemotherapy in patients with stage ⅠB1-Ⅱ high-risk cervical cancer

作　　者：朱艳[1] 刘夏星 滕薇 雷静[1] ZHU Yan;LIU Xiaxing;TENG Wei;LEI Jing(Department of Gynaecology and Obstetrics,Baoji Maternal and Child Health Care Hospital,Baoji 721000,Shaanxi,China)

机构地区：[1]宝鸡市妇幼保健院妇产科,陕西宝鸡7210000

出　　处：《癌症进展》2023年第24期2746-2748,2771,共4页Oncology Progress

基　　金：陕西省重点研发计划项目(2021SF-211)。

摘　　要：目的探讨术后同步放化疗治疗ⅠB1~Ⅱ期高危宫颈癌患者的疗效及安全性。方法根据术后治疗方法的不同将98例ⅠB1~Ⅱ期高危宫颈癌患者分为A组(n=61,同步放化疗)和B组(n=37,单纯化疗)。两组患者均随访5年,比较两组患者的复发、远处转移及生存情况。比较两组患者治疗期间不良反应发生情况。结果A组患者术后3、5年复发率及远处转移率均低于B组(P﹤0.05)。两组患者3年生存率比较,差异无统计学意义(P﹥0.05);A组患者5年生存率高于B组(P﹤0.05)。两组患者胃肠道反应、骨髓抑制、肝肾功能损伤发生情况比较,差异均无统计学意义(P﹥0.05)。结论与单纯化疗相比,同步放化疗能够降低ⅠB1~Ⅱ期高危宫颈癌患者术后3、5年复发率及远处转移率,提高5年生存率,且不增加不良反应。Objective To explore the efficacy and safety of postoperative concurrent radiochemotherapy in patients with stage ⅠB1-Ⅱ high-risk cervical cancer.Method A total of 98 patients with stage ⅠB1-Ⅱ high-risk cervical cancer were divided into group A(n=61,received concurrent radiochemotherapy)and group B(n=37,received chemotherapy alone)according to different postoperative treatment.The recurrence,distant metastasis and survival of the patients after 5 years of follow up,and incidence of adverse reactions during treatment were compared between the two groups.Result The 3-year and 5-year recurrence rates and distant metastasis rates in group A were significantly lower than those in group B(P<0.05).There was no significant difference for the 3-year survival rate between the two groups(P>0.05).The 5-year survival rate in group A was higher than that in the group B(P<0.05).There were no significant differences for the incidence of gastrointestinal reactions,bone marrow suppression,and liver and kidney function injury between the two groups(P>0.05).Conclusion Compared with chemotherapy alone,concurrent radiochemotherapy in patients with stage ⅠB1-Ⅱ high-risk cervical cancer can significantly reduce the 3-year and 5-year recurrence rates and distant metastasis rates and increase the 5-year survival rate without increasing adverse reactions.

关 键 词：高危宫颈癌 同步放化疗 复发 远处转移 生存 

分 类 号：R737.33[医药卫生—肿瘤]